Novo Nordisk shares tumble as experimental obesity drug fails to beat rival treatment
Novo Nordisk shares dropped over 15 percent on Monday after its new drug failed to outperform Eli Lilly. This setback erases gains made since the Wegovy launch.
Insights:
Novo Nordisk A/S , the pharmaceutical leader headquartered in Denmark 
DK, announced on February 23, 2026, that its next-generation obesity treatment, CagriSema, underperformed Eli Lilly and Company 's tirzepatide in a recent clinical trial. The company stated that CagriSema failed to meet the trial's goal, leading to an immediate and sharp reaction from investors. The announcement triggered a drop of more than 15% in the company's shares, effectively erasing the remaining market gains that had been sustained since the initial launch of its prominent weight-loss drug Wegovy.
DK, announced on February 23, 2026, that its next-generation obesity treatment, CagriSema, underperformed Eli Lilly and Company 's tirzepatide in a recent clinical trial. The company stated that CagriSema failed to meet the trial's goal, leading to an immediate and sharp reaction from investors. The announcement triggered a drop of more than 15% in the company's shares, effectively erasing the remaining market gains that had been sustained since the initial launch of its prominent weight-loss drug Wegovy.
